Psoriasis Therapeutics Market Updates: Expected to Reach $55.8 Billion by 2031

As per the report published by Allied Market Research, the global Psoriasis Therapeutics Market was valued at $22.9 billion in 2021, and is projected to reach $55.8 billion by 2031, growing at a healthy CAGR of 9.3% from 2022 to 2031. The study analyzes the important strategies, drivers, competition, market dynamics, size, and important investment regions.

Get Sample Copy of Psoriasis Therapeutics Market Report: https://www.alliedmarketresearch.com/request-sample/3747

Key Takeaways of the Study:

• The increase in the number of people suffering from psoriasis and various other skin disorders associated with it is expected to foster the industry’s growth.
• The development of new biologics and novel pipeline drugs are also anticipated to drive the landscape with immense opportunities.
• The rise of steroid-free topicals has emerged as a new line of treatment for psoriasis skin plagues.

Key Determinants of the Market:

The growth of the global psoriasis therapeutics market is driven by the growing number of psoriasis cases and related skin disorders worldwide. Furthermore, the growing awareness among people regarding different treatments for psoriasis is predicted to create wide growth opportunities for the market over the forecast period. Moreover, the increase in development of new biologics and novel pipeline drugs is expected to foster the landscape’s growth in the coming years. However, the high cost of therapies and other health risks posed due to the medication are the major factors impeding the industry’s growth.

Segmental Analysis:

Drug Class:

• TNF-alpha Inhibitors: TNF inhibitors are biologic drugs that target and block tumor necrosis factor (TNF), a key protein involved in the inflammatory process that drives psoriasis. By inhibiting TNF, these medications help reduce the severity of psoriasis symptoms, improve skin lesions, and decrease flare-ups. Etanercept, infliximab, and adalimumab are a few examples of popular TNF-alpha inhibitors.
• Interleukin Inhibitors: These are used in psoriasis treatment that target specific interleukins, proteins involved in the inflammatory process. By blocking interleukins like IL-17, IL-23, and IL-12, these inhibitors reduce inflammation and plaque formation. Secukinumab (IL-17) and ustekinumab (IL-12/23) are a few examples of interleukin hinhibitors.

Type:

• Plaque Psoriasis: It is a chronic autoimmune skin condition characterized by red, scaly, and itchy patches called plaques. These plaques commonly appear on the elbows, knees, scalp, and lower back. The condition results from an accelerated skin cell production process and is often managed with topical treatments, phototherapy, and systemic medications.
• Psoriatic Arthritis: It is an inflammatory arthritis associated with psoriasis. It causes joint pain, stiffness, and swelling, often affecting fingers, toes, and the spine. The condition can lead to joint damage if untreated. Treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and biologics to reduce inflammation and prevent joint damage.

Route of Administration:

• Oral: It involves taking medications by mouth to manage symptoms. This includes systemic treatments like methotrexate, cyclosporine, and apremilast. These drugs help reduce inflammation and slow down the overactive immune response, offering an effective option for moderate to severe psoriasis cases.
• Topical: In this line of treatment, medications are directly applied to skin. Common treatments include corticosteroids, vitamin D analogs, and calcineurin inhibitors. These treatments help reduce inflammation, slow skin cell growth, and relieve itching and scaling, primarily for mild to moderate psoriasis cases.
• Parenteral: It involves delivering medications by injection or infusion. These treatments target specific immune pathways, reducing inflammation and controlling severe or refractory psoriasis more effectively than topical or oral therapies.

Have Any Queries? Ask Our Expert: https://www.alliedmarketresearch.com/purchase-enquiry/3747

Regional Growth Analysis:

The global psoriasis therapeutics market is also examined across various regions including North America, Europe, Asia-Pacific, and LAMEA. The market across North America held the highest share in 2021 and is expected to continue a steady growth over the forecast period. This is mainly due to the increase in prevalence of psoriasis patients across the region. Moreover, the increase in affordability to invest in highly advanced medication among people in this region is predicted to propel the regional growth of the landscape.

Recent Developments in the Industry:

• JAK and TYK2 Blockers: These are new oral medicines that have shown promising success in blocking connections in the human immune system called signaling pathways. Sotyktu is an oral medication that helps block TYK2, signaling pathway linked to psoriasis inflammation. Sotyktu can treat moderate to severe plaque psoriasis. However, Tofacitinib is a JAK inhibitor approved by FDA to treat psoriatic arthritis.
• Topicals: Roflumilast is a newly approved steroid-free cream that can be used once daily to give relief from plaques. In addition, Tapinarof is a new topical that blocks a protein called aryl hydrocarbon receptor (AHR) linked to psoriasis inflammation. HAT1 is another steroid-free topical agent being studied to treat psoriasis skin plaques. It’s an herbal cream derived from plants.
• Phototherapy: It is an ultraviolet light therapy that is used to treat psoriasis plagues with or without topical creams. Handheld phototherapy devices have gained huge popularity in this field, allowing individuals to treat plagues conveniently in their homes.

Leading Players:

• Abbvie
• Eli Lilly and Company
• Bausch Health Companies
• Johnson and Johnson
• Novan
• Amgen
• LEO Pharma
• Viatris (Mylan NV)
• Pfizer
• Novartis AG

Key Questions Answered in the Study:

• What are the key opportunities in the market?
• Which region or sub-segment is expected to drive the industry in the forecast period?
• What are the key companies operating in the landscape?

Why Choose Allied Market Research?

• Customer Research Services
• Value Chain Analysis
• Dynamics Research Methodology
• Post-sales Support
• Quality Assurance

Procure Complete Report: https://www.alliedmarketresearch.com/checkout-final/8fb12af0aa54af594349314d4907f1dc

The Allied Market Research report on the Psoriasis Therapeutics Market provides essential knowledge for stakeholders driving this ever-evolving landscape. Offering thorough analysis enables strategic decision-making and promotes innovation in the domain.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Contact Us:

David Correa

Portland, OR, United States

USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022,

UK: +44-845-528-1300

Hong Kong: +852-301-84916

India (Pune): +91-20-66346060

Fax: +1(855)550-5975

help@alliedmarketresearch.com